BWAY (BWAY) Stock Price & Analysis
BWAY (BWAY) fell 3.27% to USD 15.97 as of July 25, 2026 at 20:51 UTC, according to Nexqual real-time market data.
BWAY last closed at USD 16.51; the session ranged USD 15.82–17.29 on volume of 283,378 shares. Market capitalization is $640.87M, with a 52-week range of USD 5.68–17.35 (NGM). Source: Nexqual, July 25, 2026 at 20:51 UTC.
Key Statistics (as of July 25, 2026 at 20:51 UTC)
| Price | USD 15.97 |
|---|---|
| Change | ▼ 3.27% (down) |
| Previous Close | USD 16.51 |
| Open | USD 17.03 |
| Day Range | USD 15.82 – 17.29 |
| 52-Week Range | USD 5.68 – 17.35 |
| Volume | 283,378 shares |
| Market Cap | $640.87M |
| Exchange | NGM |
Technical Analysis (BWAY)
Nexqual's technical model rates BWAY "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 20:51 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58 (neutral) |
| vs SMA50 | Above (USD 15.07) |
| MACD | 0.35 (positive) |
Analyst Ratings (BWAY)
Wall Street analysts rate BWAY "Strong Buy" based on 3 analysts, with a mean price target of USD 17.67 (range USD 17–18), per Nexqual as of July 25, 2026 at 20:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 17.67 |
| High Target | USD 18 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (BWAY)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD 0.07 |
| Revenue Estimate | $16.54M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.06 vs est 0.05 ▲ beat |
| 2025-12-31 | USD 0.06 vs est 0.03 ▲ beat |
| 2025-09-30 | USD 0.02 vs est 0.02 ▼ miss |
| 2025-06-30 | USD 0.03 vs est 0.02 ▲ beat |
Source: Nexqual, July 25, 2026 at 20:51 UTC.
Financials & Fundamentals (BWAY)
| Total Revenue | $56.22M |
|---|---|
| Revenue Growth (YoY) | +34.60% |
| Gross Margin | +75.51% |
| Operating Margin | +12.91% |
| Profit Margin | +15.58% |
| ROE | +12.55% |
| Debt / Equity | 8.85 |
| Current Ratio | 3.34 |
| Total Cash | $58.64M |
| Total Debt | $6.71M |
| Free Cash Flow | $3.03M |
Source: Nexqual, July 25, 2026 at 20:51 UTC.
Financial Health Score (BWAY)
Nexqual rates BWAY's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 20:51 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 76%, operating 13% |
| Balance Sheet | Strong — $59M cash vs $7M debt, net cash position |
| Cash Flow | Solid — FCF $3M, 6% margin |
| Efficiency | Mixed — ROE 13%, ROA 3.3% |
Ownership (BWAY)
| Insider Ownership | +6.02% |
|---|---|
| Institutional Ownership | +29.81% |
| Shares Outstanding | 40.13M |
| Float | 28.44M |
| Short % of Float | +0.56% |
Source: Nexqual, July 25, 2026 at 20:51 UTC.
Leadership (BWAY)
BWAY is led by Hadar Levy (age 51), Chief Executive Officer, per Nexqual as of July 25, 2026 at 20:51 UTC.
| Chief Executive Officer | Hadar Levy (age 51) |
|---|---|
| Co-Founder & Vice-Chairman | David Zacut (age 72) |
| Co-Founder, Member of Scientific Advisory Board & Director | Abraham Zangen (age 55) |
| Chief Financial Officer | Ido Marom (age 49) |
| Vice President of Medical Affairs | Colleen Hanlon (age 45) |
Major Backers & Investors (BWAY)
Notable institutional backers of BWAY include Valor Management LLC, Masters Capital Management, LLC, Acadian Asset Management. LLC, according to Nexqual as of July 25, 2026 at 20:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Valor Management LLC | 13.24% |
| Masters Capital Management, LLC | 4.11% |
| Acadian Asset Management. LLC | 2.04% |
| Essex Investment Management Co LLC | 1.54% |
| Renaissance Technologies | 1.29% |
| ARK Invest | 0.84% |
| Cresset Asset Management, LLC | 0.78% |
| Y.D. More Investments Ltd | 0.68% |
Source: Nexqual, July 25, 2026 at 20:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STIM | Neuronetics, Inc. | USD 1.73 | ▼ 10.36% |
| KMDA | Kamada Ltd. | USD 7.06 | ▲ 0.71% |
| TATT | TAT Technologies Ltd. | USD 41.83 | ▲ 0.92% |
| APYX | Apyx Medical Corporation | USD 3.92 | ▲ 0.26% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 20:51 UTC. This page is informational and not investment advice.